Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812013 | 1.00 | GSK3B (0.32) | GSK3B | |
| SCHEMBL3767653 | 0.81 | — | — | |
| SCHEMBL4811123 | 0.81 | GSK3B (0.32) | GSK3B | |
| SCHEMBL10743466 | 0.81 | GSK3B (0.32) | GSK3B | |
| SCHEMBL3767656 | 0.81 | — | — | |
| SCHEMBL14257118 | 0.81 | — | — | |
| SCHEMBL4884095 | 0.81 | GSK3B (0.32) | GSK3B | |
| SCHEMBL9651149 | 0.79 | GSK3B (0.32) | GSK3B | |
| SCHEMBL9651049 | 0.79 | GSK3B (0.32) | GSK3B | |
| SCHEMBL9651052 | 0.79 | GSK3B (0.32) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470786-B2 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2008-12-30 | — | — | US | disclosed |
| US-7452990-B2 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2008-11-18 | — | — | US | disclosed |
| US-20080200670-A1 | METHOD FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM | LUPIN LIMITED (RESEARCH PARK) (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-03-01 | — | — | US | disclosed |
| US-20070015917-A1 | Method For Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-01-18 | — | — | US | disclosed |
| WO-2006067803-A1 | A NOVEL INTERMEDIATE FOR THE PREPARATION OF CEFEPIME | LUPIN LIMITED (IN) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135761-A1 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2006-06-22 | — | — | US | disclosed |
| EP-1575913-A1 | NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES | Lupin Limited (IN) | 2005-09-21 | — | — | EP | disclosed |
| US-20050059821-A1 | Method for manufacture of ceftriaxone sodium | DATTA DEBASHISH (IN) | 2005-03-17 | — | — | US | disclosed |
| US-20050059820-A1 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2005-03-17 | — | — | US | disclosed |
| US-5109131-A | METHOD FOR PRODUCTION OF T-BUTYL 3-OXOBUTYRATES AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-04-28 | — | — | US | disclosed |
| CN-1014408-B | PREPARATION OF 4-HALOGENO-2-OXYIMINO-3-OXOBUTYRIC ACID | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1991-10-23 | — | — | CN | disclosed |
| EP-0324418-A2 | Method for production of t-butyl- 3-oxobutyrates and their use | Takeda Chemical Industries, Ltd. (JP) | 1989-07-19 | — | — | EP | disclosed |
| US-4845257-A | 4-halogeno-2-oxyimino-3-oxobutyric acids and derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-04 | — | — | US | disclosed |
| CN-87103668-A | 4-halo-2-oximino-3-ketobutyric acid | — | 1988-04-13 | — | — | CN | disclosed |
| EP-0246603-A2 | 4-Halogeno-2-Oxyimino-3-Oxobutyric acids | Takeda Chemical Industries, Ltd. (JP) | 1987-11-25 | — | — | EP | disclosed |
| US-4365062-A | BACTERICIDAL ANTIBIOTICS | RHONE-POULENC INDUSTRIES (FR) | 1982-12-21 | — | — | US | disclosed |
| US-4307116-A | BACTERICIDES | RHONE-POULENC INDUSTRIES (FR) | 1981-12-22 | — | — | US | disclosed |
| US-4307233-A | ANTIBACTERIAL AGENTS | RHONE-POULENC INDUSTRIES (FR) | 1981-12-22 | — | — | US | disclosed |
| US-4307230-A | ANTIBIOTICS | RHONE-POULENC INDUSTRIES (FR) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | TREH, CHAT, MRPL21 | GSK3B 841/4885 |
| US-20050059820-A1 | Method for manufacture of ceftriaxone sodium | TREH, CHAT, MRPL21 | GSK3B 841/4885 |
| US-20070015917-A1 | Method For Manufacture of Ceftriaxone Sodium | TREH, CHAT, MRPL21 | GSK3B 841/4885 |
| US-20080200670-A1 | METHOD FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM | CHAT, TREH, MRPL21 | GSK3B 702/4885 |
| US-20060135761-A1 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | CYP2F1, CYP2W1, CYP4F11 | GSK3B 351/4885 |
| US-20050059821-A1 | Method for manufacture of ceftriaxone sodium | TREH, CHAT, MRPL21 | GSK3B 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.